Chapter 15 of 25
- Vaginal brachytherapy: dose close to the vaginal cuff
- Pelvic external beam: a wider planned pelvic field
- Systemic treatment: addresses disease beyond a local radiation field
What you will learn
- Distinguish vaginal brachytherapy from external-beam treatment.
- Understand local-control benefits and their limits.
- Prepare for short- and long-term side effects.
Vaginal brachytherapy
After hysterectomy, the upper vagina is called the vaginal cuff. Brachytherapy places a temporary applicator in the vagina to deliver radiation close to this area. It is commonly used when reducing vaginal recurrence risk is useful but treating the whole pelvis is unnecessary. Sessions are usually outpatient, with the schedule individualized by the radiation team.
The applicator is positioned carefully; tell the team about pain, prior trauma or difficulty with examinations. In usual high-dose-rate treatment, the radioactive source is removed after the session, so the patient does not remain radioactive. Local soreness, discharge and later dryness or narrowing can occur. The team should provide a plan for vaginal and sexual health.
External-beam radiotherapy
External-beam treatment directs radiation from a machine toward the pelvis or another target. Planning CT, and sometimes MRI information, helps define the tumour bed, lymph-node regions and organs to protect. Modern techniques such as IMRT shape dose to reduce exposure to bowel, bladder and other tissues, but cannot remove all risk.
Pelvic radiotherapy can reduce pelvic recurrence in appropriate risk groups. It does not treat every possible distant microscopic cell, so chemotherapy may also be considered for higher systemic risk. Selected medically inoperable localized cancers can receive definitive radiation, often combining external treatment with brachytherapy.
What the trials teach
PORTEC-1 showed that pelvic radiation reduced local and regional recurrence in selected early-stage patients without establishing an overall-survival benefit. PORTEC-2 supported vaginal brachytherapy for selected high-intermediate-risk patients, with good vaginal control and less bowel burden, although pelvic recurrence was higher than with pelvic radiation. These studies used historical risk and staging definitions.
PORTEC-3 compared chemoradiotherapy with radiation alone in high-risk disease and found a long-term survival benefit. GOG-258 asked a different question, comparing chemoradiotherapy with chemotherapy, and found improved local control without an overall-survival improvement. The comparator and patient population matter; neither result means that every patient should receive every treatment.
Side effects and supportive care
| During or soon after treatment | Possible later effects |
|---|---|
| Fatigue, loose stools, urinary frequency or irritation | Persistent bowel or bladder changes |
| Nausea or pelvic discomfort | Vaginal dryness, narrowing or painful intercourse |
| Skin irritation in some treatment areas | Lymphoedema, pelvic bone insufficiency fracture or other uncommon injury |
Report diarrhoea, dehydration, painful urination or bleeding rather than assuming nothing can help. Nutrition advice should adapt to symptoms; restrictive diets are not routinely necessary for everyone. Vaginal moisturizers, lubricants, dilator guidance when appropriate and pelvic-floor support can help after healing. Recommendations should respect comfort, sexual activity and preferences.
Recurrence and prior radiation
An isolated vaginal recurrence in someone who has not previously received pelvic radiation can sometimes be treated with curative-intent external radiation and brachytherapy. Prior radiation changes the safety limits; reirradiation requires specialist review of the original dose plan and alternatives. A recurrence should not automatically be labelled incurable or automatically assumed suitable for more radiation.
Questions and take-home messages
Ask what area is treated, the expected benefit, whether chemotherapy is also needed and how bowel, bladder and sexual health will be supported. Obtain a contact route for symptoms and a written follow-up plan. Radiotherapy decisions should use the final pathology and molecular risk context.
Related chapters
References and review status
- PORTEC-1: fifteen-year outcomes, 2011
- PORTEC-2: ten-year outcomes, 2018
- PORTEC-3: ten-year outcomes and molecular analysis, 2025
- NRG/GOG-258: long-term overall survival, 2025
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy